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Introduction: Despite the lack of randomized evidence, stereotactic 
body radiotherapy (SBRT) is being accepted as superior to conven-
tional radiotherapy for patients with T1-2N0 non–small-cell lung 
cancer in the periphery of the lung and unfit or unwilling to undergo 
surgery. To introduce SBRT in a system of coverage with evidence 
development, a correct financing had to be determined.
Methods: A time-driven activity-based costing model for radio-
therapy was developed. Resource cost calculation of all radiotherapy 
treatments, standard and innovative, was conducted in 10 Belgian 
radiotherapy centers in the second half of 2012.
Results: The average cost of lung SBRT across the 10 centers 
(6221€) is in the range of the average costs of standard fractionated 
3D-conformal radiotherapy (5919€) and intensity-modulated radio-
therapy (7379€) for lung cancer. Hypofractionated 3D-conformal 
radiotherapy and intensity-modulated radiotherapy schemes are less 
costly (3993€ respectively 4730€). The SBRT cost increases with 
the number of fractions and is highly dependent of personnel and 
equipment use. SBRT cost varies more by centre than conventional 
radiotherapy cost, reflecting different technologies, stages in the 
learning curve and a lack of clear guidance in this field.
Conclusions: Time-driven activity-based costing of radiotherapy is 
feasible in a multicentre setup, resulting in real-life resource costs 
that can form the basis for correct reimbursement schemes, support-
ing an early yet controlled introduction of innovative radiotherapy 
techniques in clinical practice.
Key Words: Stereotactic body radiotherapy, Intensity-modulated 
radiotherapy; 3D-conformal radiotherapy; Innovation; Cost calcula-
tion; Activity-Based Costing; Non–small-cell lung cancer; Early stage.
(J Thorac Oncol. 2015;10: 454–461)
Stereotactic body radiotherapy (SBRT) uses X-ray imaging devices and sometimes implanted fiducials to accurately 
deliver high irradiation doses to an extracranial target in one 
or a few fractions, while optimally sparing healthy tissue. For 
patients with T1-2N0 non–small-cell lung cancer, peripher-
ally located and unfit or unwilling to undergo surgery, there is 
now considerable nonrandomized evidence supporting SBRT 
as superior to conventional radiotherapy with respect to local 
control and survival.1,2 SBRT is also more convenient for the 
patient and society because of reduced treatment sessions and 
related travel.
Lung SBRT can be delivered with various types of 
equipment, be it classical linear accelerators—adapted 
with advanced imaging features—or dedicated stereotactic 
machines. Moreover, different treatment techniques are used. 
They range from free breathing without motion adaptation 
over free breathing with real-time tumor tracking to tech-
niques employing some type of breathing control such as gat-
ing or breath-hold. The ensuing variety in capital resources 
and in more or less time- and resource-demanding techniques 
is doomed to translate into a range in costs. Similarly, the 
different machines and treatment approaches may engender 
differences in outcome. But although the more advanced 
methods produce superior dosimetric profiles with the poten-
tial of better organ-sparing and decreased toxicity, it remains 
unclear whether this conveys a significant improvement in 
clinical outcome.
Before marketing, manufacturers of new radiotherapy 
equipment have to prove that it safely does what it is designed 
for: delivering radiotherapy. However, health care payers want 
evidence that innovative treatments also benefit the patients. 
To date, no level 1 evidence—often requested for reimburse-
ment—exists for lung SBRT, but several randomized con-
trolled trials are ongoing to confirm its clinical superiority 
over conventional radiotherapy (and potentially also over sur-
gery) for early stage non–small-cell lung cancer.
In order not to withhold patients from receiving this 
promising novel technology, the Belgian obligatory health 
insurance initiated a coverage with evidence development 
project.3–5 The appropriate financing level in this project was 
defined in a comprehensive cost calculation study of standard 
and innovative radiotherapy, conducted in Belgian radiother-
apy departments.5
The presented analysis focuses on the cost of SBRT in 
the context of curative intent radiotherapy for lung cancer.
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MATERIALS AND METHODS
Participating Centers
The primary objective to provide input for a cost-based 
coverage of innovative radiotherapy required a costing analy-
sis assessing actual resource costs from the perspective of the 
health care provider. Ten Belgian radiotherapy centers, rep-
resentative for all 25 centers in Belgium, participated in this 
study. A mix was ensured in terms of university versus non-
university hospitals, region (Flanders, Wallonia, Brussels) and 
ownership (public versus private nonprofit).
Time-Driven Activity-Based Costing
Activity-based-costing (ABC) is an advanced cost-
accounting technique, developed in the manufacturing indus-
try of the eighties, to optimize cost calculation in case of high 
product complexity and diversity. ABC tackles the problem 
of resources that are not directly traceable to a single product 
(so-called indirect costs) in a step-wise approach: resource 
costs are first allocated to activities using “resource drivers” 
(in practice often time percentages), the calculated activity 
costs are further assigned to the products (services or treat-
ments) through “activity drivers” (e.g., number of times an 
activity is performed).6 The product cost is calculated by sim-
ply adding all costs assigned to that product.
Whereas the original ABC-methodology typically 
required a large number of diverse cost drivers, time-driven 
activity-based costing (TDABC) reduced the necessary 
parameters at each process step to only two: the cost, per time 
unit, of each of the resources used in the process and the time 
spent with each resource.7
The practical scheme and components of any TDABC 
model is unique for the specific situation and starts from a 
detailed process analysis. Radiotherapy being a predictable 
process of subsequent activities with a large share of indi-
rect costs (capital, personnel, overhead), TDABC has been 
used to evaluate the budgetary impact of new technologies 
and process changes in radiotherapy. We adapted an earlier 
departmental TDABC experience8,9 to meet the needs of this 
multi-institutional study.
Resource costs: The study followed the guidelines of 
the Belgian Health Care Knowledge Centre (KCE) “Manual 
for Cost-Based Pricing for Hospital Interventions”.10 The 
resources included in the model are based on real-life practice, 
not on normative, efficient or standard resource use.
Average annual wage costs from the KCE manual were 
applied to each fulltime equivalent.
For equipment costs, the actual purchase price was used. 
As the cost of long-term loans for financing the assets was 
included in the overhead rate and the available data on purchase 
prices did not show a clear price evolution over the years, a zero 
inflation was assumed. Hence, the annual equipment cost was 
obtained by dividing the actual purchase price by the number 
of useful years, i.e., the actual equipment life-time with a mini-
mum of 5 years for software and 10 for all other equipment.
Material costs differentiated between costs directly 
traceable to individual patients (i.e., masks and fiducials) and 
indirect consumables that apply to the entire departmental 
activity (e.g., pharmacy or office goods).
For overhead costs the hospital-wide overhead proxy 
from the KCE manual was used (Supplementary Appendix 1, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A744), adding 56.6% to all other costs excluding physician 
costs. It comprises costs of administrative personnel, blue-
collar workers and engineers, top and middle management, all 
depreciations and maintenance (except for medical equipment), 
general, cleaning, heating, financial, and administration costs.
Activities. All activities in the process of providing exter-
nal beam radiotherapy to a specific patient, from first consulta-
tion, over treatment preparation, delivery and quality assurance 
(QA) to treatment completion, were included and labeled 
“treatment-related activities” (Table 1). They were grouped 
TABLE 1.  Activity Groups and Activities for Treatment-
Related Work in External Beam Radiotherapy
Activity Groups Activities
First patient contact Create and/or fill in patient file
Intake consultation
Set appointments
Medical review
Simulation Make immobilization system
Inject contrast product
Simulation with basic imaging
Additional imaging (PET-CT, MRI)
Gating preparation
Treatment prescription
Administrative tasks
Delineation Image fusion
Target volume delineation
Indicate organs at risk
Planning Make radiation plan
Clinical check radiation plan
Finalize plan
Cross control
Medical review
Delineation of reference images
Dosimetric checks
Secondary simulation for 
adaptive radiotherapy
Secondary simulation for adaptive radiotherapy
Deliver treatment  
session
Pretreatment check and prepare imaging
Delineation of reference images
Equipment QA per patient for specific treatments
Positioning (online matching is included)
Imaging
Irradiate patient
Off-line checks (in vivo dosimetry)
Off-line checks (matching)
Evaluation CT
Regular review patient file
Consultation
End of treatment Release patient
Core treatment-related activities, in italic font: times were measured in all centres. 
Other treatment-related activities, in regular font: times were estimated in all centres.
QA, quality assurance; PET-CT, positron emission tomography-computed 
tomography; MRI, magnetic resonance imaging.
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into seven activity groups (Table 1). “Support activities” are not 
related to single patients but to the entire process. Of these, per-
sonnel costs related to equipment maintenance and QA were 
reallocated to the equipment costs (Fig. 1), whereas personnel 
costs related to other support activities were accounted for by 
the productivity-scaling factor (see further).
Cancer diagnosis, multidisciplinary consultations pre-
ceding referral to and follow-up consultations after radiother-
apy were not part of the treatment as defined for this project. 
Activities related to research and education were also considered 
“out-of-scope” (Supplementary Appendix 2, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A745).
Products. Radiotherapy treatments were defined as a 
combination of an indication or tumor type, a technique and 
the number of fractions.
Cost allocations. The largest cost components, person-
nel and equipment, followed the stepwise TDABC allocation 
procedure. Time data for treatment-related activities were 
measured or reported by the personnel concerned. Bottom-up 
calculations were performed multiplying time by the number 
of times each activity was performed annually. For person-
nel costs, these time data were multiplied with a scaling fac-
tor compensating for personnel productivity (i.e., differences 
between the bottom-up calculated time and the theoretically 
available annual hours per fulltime equivalent) and for support 
activities (e.g., meetings, machine start-up), thus ensuring that 
the totality of personnel costs is allocated to the treatments.
Overhead was allocated top-down, based on two dif-
ferent scenarios. The first applied the overhead percentage 
of 56.6 at the treatment cost level. In the second, the 56.6% 
was first calculated at the departmental level. Consequently, 
80% of this departmental overhead-pool was allocated to the 
treatments through a fixed cost per fraction, 20% through a 
fixed cost per patient. In general, we report the average of 
both scenarios.
Material costs were allocated by fraction, except masks 
and fiducials that were directly traced to the treatment.
Figure 1 depicts the entire cost allocation procedure.
The step-wise approach in practice. Data collection was 
performed in the second half of 2012, time measurements were 
conducted during a 1-month period. All centers were asked to list 
personnel and capital resources (with purchase date and price).
Next, a process analysis of the entire radiotherapy work-
flow was carried out. This determined the activities that com-
pose the treatments and were used in the model (Table 1). For 
the core activities, time registrations were carried out in all 
centers (Supplementary Appendix 3, Supplementary Digital 
Content 3, http://links.lww.com/JTO/A746). Extrapolations 
were made, based on similarity of indications and treatment 
complexity, if needed to cover for missing values. For the other 
treatment-related activities, the radiotherapy team provided 
self-reported time estimates. The same goes for the percentage 
of time devoted to out-of-scope activities, which was subtracted 
from the theoretically available time per personnel category.
Finally, each centre first produced its own list of radio-
therapy treatments offered, together with the yearly number 
of patients treated (for 2011 or 2012). For the purpose of the 
multicentre analysis, the research team grouped the treatments 
delivered by organ system and complexity. Lung treatments 
delivered with curative intent were grouped by fractionation 
and technique: 3D-conformal radiotherapy (3D-CRT), inten-
sity-modulated radiotherapy (IMRT), and SBRT (free breath-
ing without motion adaptation versus gating and tracking). 
For 3D-CRT and IMRT, hypofractionated schemes (12 to 20 
fractions) were analyzed separately from conventional frac-
tionation (30 to 35 fractions).
RESULTS
Table 2 shows the input variables, resources as well as 
operational parameters, used in the model.
Out of scope
Treatment cost
DIRECTINDIRECT
Personnel MaterialEquipment
Treatment related activities Support activities
Intake 
consultation
Medical 
review …
IMRT lung 
30 fractions
SBRT lung 
5 fractions …
Overhead
Other
Equipm. 
maint.
& QA
Material
Time driven
Activity 
consumption Per fraction
Department level Product level
56.6%
FIGURE 1.  Cost allocation model. The topmost part of the figure shows the different costs: personnel, equipment, overhead, 
and direct and indirect material. The lower part shows how these costs were allocated to the different treatments. Indirect 
costs: costs that cannot be directly assigned to a single treatment, i.e., personnel, equipment, overhead, and indirect material. 
Personnel and equipment costs: TDABC two-step methodology. Overhead costs: defined at treatment or departmental level 
(allocated by fraction and by patient). Indirect material costs: allocated by fraction. Direct costs: costs directly assigned to a 
specific treatment, i.e., direct material costs (masks, fiducials). TDABC, time-driven activity-based costing.
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TABLE 2.  Costs and Operational Data
Input Parameters Average Range n Source
Costs
Equipment
Capital cost (purchase price)
  Treatment machines (per machine)
   Linear accelerators 1,988,248 € 1,398,896€–2,498,143€ 46 Data collection
   Dedicated SBRT machines 4,414,950 € 2,286,900€–6,543,000€ 2 Data collection
  Simulators (per machine)
   Conventional simulator (± cone beam CT) 768,775 € 362,891€–1,951,862€ 5 Data collection
   CT simulator 680.668 € 478,907€–850,000€ 7 Data collection
  Planning systems (per department) 920,569 € 274,558€–2,174,606€ 10 Data collection
Annual external maintenance contract
  Treatment machines (per machine)
   Linear accelerators 115,510 € 637€–193,853€ 46 Data collection
   Dedicated SBRT machines 264,960 € 225,000€–304,920€ 2 Data collection
  Simulators (per machine)
   Conventional simulator (± cone beam CT) 29,737 € 9530€–59,423€ 5 Data collection
   CT simulator 78,257 € 50,400€–122,177€ 7 Data collection
  Planning systems (per department) 35,673 € None–242,324€ 10 Data collection
Life span for depreciation
  Treatment machines, simulators Actual life-time, with minimum 10 years 10–17 years Data collection, expert opinion
  Planning systems Actual life-time, with minimum 5 years 5–17 years Data collection, expert opinion
Personnel (annual cost per FTE)
  Radiotherapy nurses 64,465 € KCE manual (10)
  Dosimetrists/planners 59,906 € KCE manual (10)
  Physicists 82,780 € KCE manual (10)
  Senior radiation oncologists 256,241 € KCE manual (10)
  Junior radiation oncologists 43,771 € KCE manual (10)
Overhead
  % resource costs excluding physician cost 56.60% KCE manual (10)
Operational parameters
  Department size
   Number of treatment machines 4.8 2–7 10 Data collection
  Productivity
   Department operational hours 50 h/week Expert opinion
   Treatment machine utilization
    Linear accelerators 81.4% 9%–167% 46 Data collection
    Dedicated SBRT machines 31.5% 31%–32% 2 Data collection
   Annual fractions/treatment machine
    Linear accelerators 8488 6011–12,815 46 Data collection
    Dedicated SBRT machines 773 580–966 2 Data collection
   Annual courses/treatment machine
    Linear accelerators 419 281–501 46 Data collection
    Dedicated SBRT machines 109 91–127 2 Data collection
   Annual hours/FTE (nurses, dosimetrists, physicists) 1605 KCE manual (10)
   Annual half days/FTE (radiation oncologists) 482 KCE manual (10)
  Number of fractions per lung treatmenta
   Hypofractionation
    3D-conformal radiotherapy 17 12–20 300 Data collection
    Intensity-modulated radiotherapy 15 13–20 15 Data collection
(Continued)
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The overall yearly number of lung radiotherapy treat-
ments delivered with curative intent varied by centre from 46 
to 252, the lung SBRT treatments from 7 to 73 (mean 40).
Figure 2A shows the average cost by treatment type, 
with a breakdown per resource cost item and for both over-
head scenarios. The major cost items both for conventional 
radiotherapy and SBRT are personnel and equipment, fol-
lowed by overhead. Material costs are negligible. Overhead 
allocated at the treatment level results in higher overhead 
costs for expensive treatments, regardless of fraction num-
bers. Conversely, overhead allocated at the departmental level 
induces higher overhead costs for long treatment schedules 
and lower for hypofractionated schedules, including SBRT.
The overall average cost (in 2011 Euro) of lung SBRT is 
6221€ (range by centre: 3104€–12,649€), of standard frac-
tionated 3D-CRT: 5919€ (4557€–6564€) and IMRT: 7379€ 
(5054€–8733€); of hypofractionated 3D-CRT: 3993€ 
(3674€-4380€) and IMRT: 4730€ (single centre).
Figure 2B demonstrates that the cost per individual cen-
tre varies more considerably for SBRT than for conventional 
radiotherapy techniques.
In spite of fewer fractions (Fig. 3B), the average lung 
SBRT cost is close to that of standard fractionated radiother-
apy, due to higher demands of time and personnel qualifica-
tions (Fig. 3C–D), whereas fewer fractions translate into lower 
costs for hypofractionated schedules.
Figure 4 depicts the variation in average cost by SBRT 
modality, fractionation and centre.
DISCUSSION
Cost–effectiveness analyses are typically conducted 
from the health care payer perspective; hence use health 
care payer costs (charges, reimbursement) of the interven-
tions studied.11–13 In the US, the reported health care payer 
cost of lung SBRT is lower than that of conventionally frac-
tionated external beam radiotherapy, mainly 3D-CRT.13 The 
reimbursement rates for both the technical and professional 
components may however not always reflect the real cost for 
the health care provider.
It is well known that over- and under-financing of a spe-
cific radiotherapy technique may stimulate or limit its use, a 
phenomenon not limited to radiotherapy. For example, high 
Medicare reimbursement clearly fuelled the uptake of IMRT 
for prostate cancer and resulted in overuse in US.14 Similarly, 
fee-for-service reimbursement endorsing the use of fraction-
ated schedules limited the uptake of single fraction radio-
therapy in the palliation of bone metastases.15,16 A financially 
correct coverage is therefore a prerequisite for the appropri-
ate use of medical interventions, and this is also valid when 
an innovative intervention is introduced. This underscores the 
need for accurate resource cost data.
Due to the typical incremental evolution of new radiother-
apy technologies and techniques, it may at onset be difficult to 
appreciate whether the cost will decrease with time due to more 
optimal resource utilization or in contrast increase because of 
progressive complexity. ABC has been proposed to capture the 
financial impact of gradual process and technology changes in 
radiotherapy.17 Until now, this method has predominantly been 
used to compute the costs for individual departments, specific 
techniques or in analytic models,8,9 but not to compare real-life 
costs among operational departments. Moreover, to the best of 
our knowledge, this is the first multi-institutional assessment of 
the cost of SBRT compared to more conventional radiotherapy 
from a health care provider perspective.
Some methodological limitations were encountered dur-
ing data collection and analysis. It was not realistic to perform 
time measurements for all activities; hence we relied on self-
reported time estimates for noncore and out-of-scope activities. 
Time measurements were sometimes lacking during the mea-
surement period for infrequent activities in less frequent treat-
ment types. To cover for missing values, extrapolations were 
made based on similarity of indications and treatment complex-
ity. Finally, as the product definition was left at the discretion of 
each individual centre, queries were needed to fully understand 
the details of each treatment reported and to allow grouping of 
treatments by type across centers. We are nevertheless confident 
that due to the size of the data collection the presented data 
adequately reflect the actual resource costs.
   Conventional fractionation
    3D-conformal radiotherapy 31 30–35 433 Data collection
    Intensity-modulated radiotherapy 32 30–35 166 Data collection
   SBRT
    Free breathing 5 3–10 272 Data collection
    Gating 5 3–8 50 Data collection
    Tracking 7 3–10 70 Data collection
  Treatment time slot (in min)b
   3D-conformal radiotherapy 16 12–20 677 Data collection
   Intensity-modulated radiotherapy 20 17–26 288 Data collection
   SBRT 35 22–64 89 Data collection
aEvaluation at treatment level.
bEvaluation at fraction level.
n, number of data points; FTE, fulltime equivalent; SBRT, stereotactic body radiotherapy; CT, computed tomography.
TABLE 2.  (Continued)
Input Parameters Average Range n Source
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A B
C D
FIGURE 3.  Determinants of time and 
resource use (averages and range at centre 
level). A, Cost. B, Fractions. C, Time * per-
sonnel use during preparation. D, Time * 
personnel use during treatment delivery.
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FIGURE 2.  Average lung cancer radiotherapy cost. A, Breakdown per resource cost item and for both overhead scenarios. B, 
Global averages (bars) versus averages per individual centre (dots).
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In addition to these methodological issues, we are aware 
that the presented costs may not be completely generalizable 
to other jurisdictions, a problem frequently encountered—yet 
often neglected—when it comes to cost computations and 
other economic analyses in health care. The details presented in 
Table 2 should, however, offer the reader the necessary details to 
judge whether our data are applicable to his/her country.
We computed an average resource cost of 6221€ for 
lung SBRT in Belgium. This cost, calculated from the health 
provider perspective in Belgium, is considerably lower than 
typical reimbursement figures reported for other jurisdic-
tions. In the USA, charges ranging between 10,000$ and 
15,000$ are common.11–13 On the contrary, our real-life costs 
are higher than the costs computed in a theoretical model for 
the Netherlands. Based on 2007 price levels, an average cost 
for lung SBRT of 3720€ (range: 930€–9310€) was reported. 
However, extremely high productivity levels (98% treatment 
room availability, 100% utilization) and machine throughputs 
(2287 patients per year in two treatment rooms) were assumed, 
which can hardly be achieved real-life, as demonstrated by our 
data (Table 2).18
The average lung SBRT cost is very similar to the aver-
age cost of standard fractioned 3D-CRT (5919€) and lower 
than that of IMRT (7379€). There are various drivers of SBRT 
cost: the technique itself; the cost of the system(s) used and 
its occupancy level; the duration of specific activities and the 
education level of the personnel performing them, in par-
ticular senior radiation oncologists and physicists. Not sur-
prisingly, for a given technique and centre, the cost of SBRT 
increases with the number of fractions, in line with the cost of 
hypofractionated radiotherapy being lower than that of more 
protracted conventional fractionation schedules.
Low costs for SBRT were found in centers where the 
time measures for treatment-related activities were similar 
for SBRT and IMRT, as well as the equipment used and the 
personnel present during treatment delivery. They were also 
seen in case older linear accelerators were used or when the 
department was globally understaffed. The two highest SBRT 
costs had different main drivers, although in both cases, costs 
are expected to drop considerably in the future. In one cen-
tre, the senior radiation oncologist was mostly present dur-
ing the lengthy treatment sessions, reflecting an early phase in 
the learning curve. In the other centre, a dedicated real-time 
tracking system was used. The associated treatment cost was 
found to be high for three reasons. First, the machine cost is 
higher than for a nondedicated linear accelerator. Second, a 
low machine occupation level is a critical determinant of cost: 
increasing the occupation level from the current 30% to 90% 
would nearly half the cost of lung SBRT. This would require 
the introduction of SBRT for additional indications or to 
select patients from a wider catchment area. Similar findings 
have been reported for another dedicated system for stereo-
tactic brain irradiation, which may be cost competitive only 
if demand for these services is high enough to fully use the 
equipment working time.19 Third, even at full capacity, track-
ing SBRT will remain somewhat more costly compared with 
other SBRT modalities due to a higher beam-on time. Any 
clinical benefit of the higher cost of tracking SBRT over other 
SBRT modalities is yet to be demonstrated.
Regardless of the cost implications and independent 
of the SBRT technique used, access to a minimum number 
of patients to build and maintain the necessary expertise and 
assuring high quality radiotherapy may require more central-
ization of such complex treatments. In our study centers, the 
level of expertise and the QA measures differed, pointing to 
the need for clear guidance in this area.
The large variety observed in our study in terms of 
costs, reflecting differences in technology and respective unit 
costs, practice and timing in the learning curve, make it hard 
for the policy maker to define a correct reimbursement level. 
Nor the most advanced technique with the highest cost, nor 
the cheapest approach, potentially mirroring understaffing, 
less appropriate equipment and/or quality levels, are a good 
basis for reimbursement setting. These uncertainties taken 
into consideration and awaiting more (randomized) evidence, 
the Belgian obligatory health insurance initiated a CED proj-
ect for innovative radiotherapy, including SBRT, for which 
early stage lung cancer is the most evident indication. Based 
on the calculated costs presented in this report, a provisional 
financing was determined. In return, the health care provid-
ers commit themselves to evidence collection in collaboration 
with the Belgian cancer registry. The aim is to make a blue-
print of the Belgian SBRT landscape, showing the national 
distribution of indications, techniques, and practice patterns. 
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FIGURE 4.  Cost of SBRT for lung cancer by 
centre, technique and fractionation. If the reported 
fractionation overlapped with two categories, the 
same cost was reported for both. SBRT, stereotactic 
body radiotherapy.
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Thanks to the financial coverage, this project allows health 
care providers to deliver this promising new treatment to the 
patient at an early stage of technology development.
In conclusion, we demonstrated that TDABC of radio-
therapy treatments is feasible in a multicenter setup, resulting in 
robust cost calculations that can form the basis for correct reim-
bursement schemes by the health care payer, fostering an early 
introduction into clinical practice, hopefully in time translating 
into appropriate daily care with formal reimbursement.
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